Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001212667 | SCV001384259 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with tryptophan at codon 932 of the ADAMTS2 protein (p.Arg932Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs776975672, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with ADAMTS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C35"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV004792803 | SCV005411960 | uncertain significance | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing | BP4 |
Natera, |
RCV001212667 | SCV002081916 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2020-03-15 | no assertion criteria provided | clinical testing |